Established in 2018, Novatim Immune Therapeutics (Zhejiang) Co., Ltd. operates with Tinova (Shanghai) as its wholly-owned subsidiary, Focusing on pioneering advancements in cancer treatment, Novatim is dedicated to the research and clinical application of innovative cancer immunotherapy. 

Grounded in clinical needs, Novatim strives to achieve innovative breakthroughs in discovering both first-in-class and best-in-class drugs.Specializing in cancer immunotherapy research, Novatim harnesses three key platforms: the Bifunctional Antibody Platform, the Nano Dual Antibody ADC Platform, and the Enhanced Dual Target CAR-T Platform. 10 FIC/BIC products were developed based on Novatim’s technological breakthroughs.

Mission: Innovating to lead the future of medicine, excelling to safeguard life and well-being.

Vision: Pioneering the biopharmaceutical innovation.

Values: Scientific rigor, practical innovation, embracing responsibility, pursuing excellence.